HistoSonics is shopping for a potential buyer of its approach to destroying liver tumors with focused sound waves, according ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 ...

Scholar Rock is shaking up its executive team as it prepares to enter the commercial arena with the expected launch of spinal ...

To REMS, or not to REMS. That apparently was the question for Cytokinetics, which has seen any potential approval for its ...

Pliant will be cutting 45% of staffers as part of a “strategic restructuring of its workforce," the biotech announced after ...

The National Institutes of Health (NIH) is making a major change to how grant recipients can use their funds. | The National ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. | ...

The U.S. government is putting down $500 million toward the development of a “universal” vaccine—a shot designed to protect ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms.

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...